Ascendis Pharma在收到Yorvipath患者死亡报告后陷入困境

2025-10-21 06:22

Ascendis Pharma at one point on Monday was down ~12% before closing off just 2.5% after the FDA adverse event report database was updated to reflect the death of an individual taking the hypoparathyroidism drug Yorvipath (palopegteriparatide).
The database entry indicated that the patient also had HER2+ breast cancer and experienced reactions including hypocalcemia, hypocalcemic seizures, and postoperative wound infection.
A death reported to the FDA Adverse Event Reporting System does not necessarily mean a drug the patient was taking contributed to it.
Analyst Luca Issi of RBC Capital, who rates Ascendis at outperform, said that given the patient had breast cancer, had a complex clinical situation, and was on multiple medications, it is uncertain if Yorvipath caused or is even correlated with the death.

More on Ascendis Pharma